Construction of a human-size clinical MRX machine
Post# of 128
Posted On: 11/21/2014 9:52:46 AM
Re: rustydog62 #28
Construction of a human-size clinical MRX machine in 2015
Earlier this year, a poster presented at the World Molecular Imaging Conference by John D. Hazle, PhD of the MD Anderson Cancer Center, noted Senior Scientific’s MRX technology “is unparalleled in terms of sensitivity compared to imaging-based ovarian cancer detection methods” and that “it holds promise for detecting ovarian cancer much earlier.” The poster also noted that “because the technology relies on nano particles (NPs) binding to specific cancer cells and is detecting molecular markers, presumably only cancer will be detected with this technology while unbound particles in the vascular space will not be.” Further, the advantage of nanomagnetic relaxometry compared to some imaging–based technologies was highlighted as it holds “promise for detecting ovarian cancer much earlier, which is crucial to increasing survivorship.”
The Company plans to initiate construction of a human-size clinical MRX machine in 2015, which would precede submissions to the Food and Drug Administration (FDA).
CEO Manny Tsoupanarias of Manhattan Scientifics, said, “This capital will largely be invested in the important technology research at our subsidiary Senior Scientific LLC. Our developments to date are keeping us focused on scientifically proving that our MRX technology holds the potential to be a significant new tool in the fight against cancer.”
Earlier this year, a poster presented at the World Molecular Imaging Conference by John D. Hazle, PhD of the MD Anderson Cancer Center, noted Senior Scientific’s MRX technology “is unparalleled in terms of sensitivity compared to imaging-based ovarian cancer detection methods” and that “it holds promise for detecting ovarian cancer much earlier.” The poster also noted that “because the technology relies on nano particles (NPs) binding to specific cancer cells and is detecting molecular markers, presumably only cancer will be detected with this technology while unbound particles in the vascular space will not be.” Further, the advantage of nanomagnetic relaxometry compared to some imaging–based technologies was highlighted as it holds “promise for detecting ovarian cancer much earlier, which is crucial to increasing survivorship.”
The Company plans to initiate construction of a human-size clinical MRX machine in 2015, which would precede submissions to the Food and Drug Administration (FDA).
CEO Manny Tsoupanarias of Manhattan Scientifics, said, “This capital will largely be invested in the important technology research at our subsidiary Senior Scientific LLC. Our developments to date are keeping us focused on scientifically proving that our MRX technology holds the potential to be a significant new tool in the fight against cancer.”
(0)
(0)